trandolapril / Generic mfg. - LARVOL DELTA

Regulation of mechanical intercellular junctions and components of the mitochondrial electron transport chain and the TCA cycle in the hypertrophic heart by pyridostigmine or trandolapril. (PubMed, Front Mol Biosci) - "Our data indicate that adaptive remodeling in hypertensive hearts is largely governed by phosphorylation-mediated regulation of the entire area composita, particularly adherens and desmosomal junctions, highlighting the crucial role of mechanical junctions in addition to electrochemical signaling. The observed ability of trandolapril to restore phosphorylation of junctional proteins, which may contribute to the suppression of cardiac hypertrophy, underscores the importance of preserving cardiomyocyte mechanical stability in the management of hypertension-related pathologies."

Journal • Cardiovascular • Hypertension

sGC stimulator BAY 41-8543 improves survival and ventricular function in a rat model of doxorubicin-induced cardiomyopathy with nephrotic syndrome. (PubMed, Br J Pharmacol) - "The sGC stimulator BAY 41-8543 exerted significant cardioprotective effects in DOXO-induced HF. Therefore, sGC stimulators may represent a promising therapeutic option for anthracycline-induced cardiomyopathy, although additional studies are required to fully investigate their therapeutic potential."

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Glomerulonephritis • Heart Failure • Nephrology • Oncology • Renal Disease

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Recruiting | Sponsor: Policlinico San Donato S.p.A. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Adverse event of ACE inhibitors: A descriptive analysis of FAERS data. (PubMed, J Public Health Res) - "This retrospective pharmacovigilance study analyzed FAERS reports submitted from January 1, 1979, through March 31, 2025, for nine ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, and trandolapril) identified as primary suspect drugs. Adults and elderly patients carry the highest burden of ADEs, though pediatric cases remain clinically relevant for specific agents. These findings support tailored monitoring and risk mitigation strategies in clinical practice."

Adverse events • Journal • Acute Kidney Injury • Cardiovascular • Cough • Hypertension • Hypotension • Nephrology • Pediatrics • Renal Disease • Respiratory Diseases

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD) (clinicaltrials.gov) - P4 | N=64 | Active, not recruiting | Sponsor: Baylor Research Institute

New P4 trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

TAPERED-HF: The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission. (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Ziekenhuis Oost-Limburg

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Projected Volume Method for Accurate Measurement of Cross-Peak Intensity in Two-Dimensional NMR Spectra. (PubMed, Magn Reson Chem) - "Trandolapril, an angiotensin-converting enzyme (ACE) inhibitor, undergoes two-state exchange in organic solvents arising from cis-trans isomerization around a N-C bond...It also offers other useful benefits, such as a narrower projection box size to reduce the contributions of other diagonally overlapping cross-peaks in 2D HSQC spectra, the improved signal-to-noise ratio of projection spectra by slice summation, and the cancellation of dispersion components caused by spectral misphasing in the 1H dimension. These advantages and benefits increase the accuracy of cross-peak volume determination in 2D HSQC spectra, compared with existing methods that directly fit 2D cross-peak shapes."

Journal

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann

New P4 trial • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann | Unknown status ➔ Recruiting | Trial completion date: Feb 2021 ➔ Dec 2026 | Trial primary completion date: Feb 2019 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model. (PubMed, Biomed Pharmacother) - "The current study aimed to compare the combination of empagliflozin with angiotensin converting enzyme inhibition (trandolapril) versus triple therapy (hydralazine, hydrochlorothiazide, reserpine). In contrast, triple therapy combined with empagliflozin worsened most of the aforementioned effects. Our study´s results suggest that combining empagliflozin with ACE inhibition has beneficial effects, whereas combining empagliflozin with triple therapy has the opposite effect."

Journal • Inflammation • Metabolic Disorders • LEP • TNFA

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study (clinicaltrials.gov) - P=N/A | N=13656 | Not yet recruiting | Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

New trial • Real-world evidence • Cardiovascular • Infectious Disease • Pneumonia • Respiratory Diseases

Trandolapril Attenuates Pro-Arrhythmic Downregulation of Cx43 and Cx40 in Atria of Volume Overloaded Hypertensive and Normotensive Rats. (PubMed, Biomolecules) - "We investigated the impact of volume overload on Cx43 and Cx40 in right and left heart atria of hypertensive pressure overloaded Ren-2 transgenic (TGR) strain and normotensive Hannover Sprague Dawley (HSD) rats, as well as the efficacy of renin-angiotensin blockade with trandolapril and losartan. Trandolapril attenuated pro-arrhythmic downregulation of Cx43 and Cx40 in atria of volume overloaded normotensive as well as hypertensive rats. This fact as well as examining AF inducibility requires further investigation."

Journal • Preclinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

A soluble guanylate cyclase stimulator improves survival in a rat model of heart failure with reduced ejection fraction and chronic kidney disease induced by aorto-caval fistula and 5/6 nephrectomy (ESC-WCC 2025) - "One week later, ACF was created; another two weeks later, the animals were randomly divided into three groups, and the therapy was started: sGC stimulation with BAY-41-8543 (sGC stim.) (3 mg.kg-1.day-1 in food, n = 24), angiotensin-converting enzyme inhibitor (ACEi) (trandolapril, 2 mg.L-1 in drinking water, n = 24), or placebo (n = 22)...Conclusion(s) Our results indicate that in the ACF-5/6Nx TGR animal model of combined HF and CKD, treatment with an sGC stimulator reduces mortality to a similar extent as ACEi monotherapy compared to placebo. Further preclinical research is needed to better understand the NO/sGC/cGMP pathway in HF with concurrent CKD."

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Trandolapril mitigates heart connexin43 and ECM disorders in dual pressure and volume overload heart failure (ESC-WCC 2025) - "There is a benefit of treatment with trandolapril and losartan, indicating their pleiotropic anti-arrhythmic potential. This may provide novel insights into medical therapy for HF and arrhythmias."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • MMP2 • SMAD2

Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat. (PubMed, FEBS J) - "None of the binding modes of the inhibitors extend beyond the S1-S2' subsites to make use of the unique nACE/cACE residues that have been shown to influence domain selectivity. These findings supplement our understanding of ACE inhibition by the clinically used ACE inhibitors, and this information should be useful in the future design of more domain-selective inhibitors for the treatment of hypertension and cardiovascular diseases."

Journal • Cardiovascular • Fibrosis • Hypertension • Immunology

Dehydration and hypertension differently prime intrinsic and pre-renal AKI (ERA 2025) - "- Pre-renal AKI: induced by triple whammy therapy (concomitant treatment with oral doses of 0.7 mg/kg/day trandolapril, i.p. doses of 60 mg/kg/day ibuprofen, and of 20 mg/kg/day furosemide) for two consecutive days. Dehydration differently primes intrinsic and pre-renal AKI under normotension and hypertension. Thus, in normotensive animals, dehydration constitutes an important risk factor for pre-renal AKI induced by TW but not for intrinsic AKI induced by cisplatin, where loss of hydration status did not aggravate renal dysfunction observed after cisplatin treatment. However, in hypertensive animals, whereas dehydration sensitize them to intrinsic AKI caused by cisplatin, it does not constitute a risk factor for TW-induced pre-renal AKI unless sustained over the time."

Acute Kidney Injury • Cardiovascular • Hypertension • Nephrology • Renal Disease

Effect of increasing age on pre-renal AKI incidence and severity in dehydrated and normohydrated rats (ERA 2025) - " Two- and thirteen-month-old male Wistar rats were divided into three experimental groups: TW group: with free access to water during the whole experiment receiving TW therapy for two days (oral doses of 0.7 mg/kg/day trandolapril, i.p. doses of 60 mg/kg/day ibuprofen, and of 20 mg/kg/day furosemide). These results suggest that age increases the susceptibility to AKI under dehydration and TW use, and that younger rats show variability in renal homeostasis efficiency across individuals."

Preclinical • Acute Kidney Injury • Nephrology • Renal Disease

Trandolapril attenuates renal fibrosis in rats with a dual-injury model of kidney disease progression. (ERA 2025) - " We developed a transition model from acute kidney injury (AKI) to CKD, where the acute phase of the disease is induced through the administration of a nephrotoxic single dose of cisplatin (5 mg/kg). Our study provides evidence that trandolapril can mitigate the development of renal fibrosis in a rat model transitioning from AKI to CKD. This beneficial effect, observed despite the absence of hemodinamic and kidney function changes, highlights the potential of ACE inhibitors to prevent long-term structural damage and may have important implications for the management of patients at risk for CKD progression after AKI episodes."

Preclinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • Reperfusion Injury